Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adavosertib - AstraZeneca

Drug Profile

Adavosertib - AstraZeneca

Alternative Names: AZD-1775; L001739996-008U; MK-1775; MK-1775 hemihydrate

Latest Information Update: 13 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer AstraZeneca; Canadian Cancer Trials Group; Cancer Research UK; Dana-Farber Cancer Institute; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Texas M. D. Anderson Cancer Center; University of Washington
  • Class Aniline compounds; Antineoplastics; Piperazines; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Haematological disorders; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Uterine cancer; Vulvovaginal cancer

Most Recent Events

  • 31 May 2024 Adverse events and efficacy data from a phase-II trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 May 2024 Discontinued - Phase-I for Glioblastoma (Recurrent, Newly diagnosed, Combination therapy) in USA (PO)
  • 28 May 2024 Discontinued - Phase-I for Haematological disorders (Combination therapy, First-line therapy, Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top